Pure Biologics Spólka Akcyjna
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PUR.WA research report →
About the company
Pure Biologics Spólka Akcyjna operates as a biopharmaceutical enterprise, concentrating its efforts on the discovery and development of novel biological pharmaceuticals and targeted, non-systemic treatments. The company's key therapeutic interests span immuno-oncology, various autoimmune conditions, and rare diseases. Its capabilities encompass the entire process for antibodies and aptamers, from their initial creation and purification to detailed analysis and characterization.
- CEO
- Filip Jelen
- IPO
- 2018
- Employees
- 7
- HQ
- Wroclaw, PL
Price Chart
- Market Cap
- $18.92M
- P/E
- -1.63
- P/S
- 0.00
- P/B
- -1.67
- EV/EBITDA
- -4.51
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 63.00%
- ROIC
- 315.22%
- Revenue
- $0 · 0.00%
- Net Income
- $-9,820,000 · 49.47%
- EPS
- $-1.99 · 47.35%
- Op Income
- $-6,331,000
- FCF YoY
- 42.03%
- 52W High
- $9.20
- 52W Low
- $1.35
- 50D MA
- $2.35
- 200D MA
- $3.80
- Beta
- 0.25
- Avg Volume
- 528.79K
Get TickerSpark's AI analysis on PUR.WA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PUR.WA coverage
Recent articles, reports, and earnings notes.
No research on PUR.WA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PUR.WA report →Similar companies
Peers in the same neighborhood.